BMD type 1. Mania with psychotic symptoms
Conditions
Interventions
Intervention 1: Buprenorphine, 2 mg Tab, 4-6 mg for 1st day, 6-8 mg daily for 2 weeks. Intervention 2: Buprenorphine plasebo.
Treatment - Drugs
Buprenorphine, 2 mg Tab, 4-6 mg for 1st day, 6-8 mg daily for 2 weeks
Buprenorphine plasebo
Sponsors
Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age 18-65; Diagnosis of BMD type I; The initial severity of positive symptoms; Opioid abuse for 6 months before admission. Exclusion criteria: A history of methamphetamine use within 3 months; Dependence on alcohol, benzodiazepines or hallucinogens; Diagnosis of methamphetamine-induced stable psychosis ; Taking antipsychotics or mood stabilizers two weeks before admission; MR; Head damage that cause or worsen mood or psychotic features in patient; Major cognitive impairment; Development of delirium during the study 9- Disabling medical disorder 10- Consumption of opioid agonists such as buprenorphine or others two weeks before hospitalization 11- Non persian language 12- A history of coronary artery disease 13- Changes in the ECG because of angina during treatment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in psychotic symptoms. Timepoint: Week 1, week 2. Method of measurement: BPRS questionnaire.;Symptoms of opiate withdrawal. Timepoint: Week 1, week 2. Method of measurement: COWS questionnaire.;Illness severity. Timepoint: Week 1, week 2. Method of measurement: CGI questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The severity of depression. Timepoint: Week 1, week 2. Method of measurement: MARDS questionnaire.;The severity of mania. Timepoint: Week 1, week 2. Method of measurement: YMRS questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mehdi Alimardanzadeh
Shahid Beheshti hospital
Outcome results
None listed